Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa
Salt Lake City, Utah--(Newsfile Corp. - June 27, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") received approval to initiate a first-in-human clinical trial for KIO-301, which is intended to restore lost vision in patients with Retinitis Pigmentosa, a rare, inherited genetic eye disease that causes severe loss of functional vision due to degeneration of the retinal photoreceptors (rods and cones). The ABACUS study is a Phase 1b open label, single ascending dose...
2022-06-27 6:53 AM EDT
Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
Salt Lake City, Utah--(Newsfile Corp. - May 31, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced that on May 25, 2022, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2022, with...
2022-05-31 4:30 PM EDT
Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022
Salt Lake City, Utah--(Newsfile Corp. - April 25, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that the full results of the KIO-101 Phase 1b clinical trial are being presented at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting on April 25, 2022. The results of the vehicle-controlled, randomized clinical trial in patients with ocular surface inflammation demonstrated safety and tolerability of KIO-101 as well as...
2022-04-25 6:45 AM EDT
Kiora Pharmaceuticals Reports 2021 Results and Provides Business Update
Salt Lake City, Utah--(Newsfile Corp. - April 15, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today reported its financial results for the quarter and year ended December 31, 2021 and provided an update on recent corporate and operational activities. "We are making significant progress advancing our pipeline of treatments for ocular disease," said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. "KIO-301 was recently granted orphan drug...
2022-04-15 9:00 AM EDT
Kiora Pharmaceuticals to Participate in Maxim Group's 2022 Virtual Growth Conference March 28th - 30th
Salt Lake City, Utah--(Newsfile Corp. - March 21, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") has been invited to present at Maxim's 2022 Virtual Growth Conference March 28th - 30th. Company President and CEO, Brian M. Strem, Ph.D., will participate in a live ophthalmology roundtable discussion as well as provide an on-demand investor presentation. The roundtable and presentation may be viewed by registering at the following conference page -
2022-03-21 6:45 AM EDT
Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)
Salt Lake City, Utah--(Newsfile Corp. - March 18, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its investigational treatment of Retinitis Pigmentosa, KIO-301. Retinitis Pigmentosa is a rare, inherited genetic eye disease that can lead to severe loss of vision due to degeneration of rods and cones. Kiora expects to initiate clinical trials of KIO-301 in Q3 2022. Orphan...
2022-03-18 6:45 AM EDT
Kiora Pharmaceuticals Announces Participation at 2022 BIO CEO & Investor Conference
Salt Lake City, Utah--(Newsfile Corp. - February 8, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today that Brian M. Strem, Ph.D, President and CEO of Kiora, will present a Company overview at the BIO CEO & Investor Conference on February 15th at 10:30AM Eastern. The conference will be held at the Marriott Marquis in New York City from February 14th until February 17th. Kiora's presentation will be available for download from the Company's Investor...
2022-02-08 6:45 AM EST
Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board
Salt Lake City, Utah--(Newsfile Corp. - February 1, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today the appointment of Erin Parsons as a new independent Director of its Board of Directors (the "Board"). Separately, the Executive Chairman, Stephen From, has informed Kiora of his voluntary resignation from the Board. These changes are effective immediately. "I am pleased to welcome Erin Parsons to our Board of Directors," said Brian M. Strem, Ph.D,...
2022-02-01 6:45 AM EST
Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference
Salt Lake City, Utah--(Newsfile Corp. - January 5, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will participate in the H.C. Wainwright Bioconnect Virtual Conference January 10-13, 2022. Brian Strem, Ph.D., President and Chief Executive Officer, will provide an outlook for the business and its pipeline of treatments for ophthalmic diseases. The corporate presentation will be available on-demand and accessible from the Company's Investor Relations website starting Monday January 10, 2022...
2022-01-05 7:00 AM EST
Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors
Salt Lake City, Utah--(Newsfile Corp. - December 15, 2021) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced the appointment of David Hollander, MD, MBA, to its Board of Directors. Dr. Hollander, who currently serves as the Chief Research and Development Officer of Aerie Pharmaceuticals, Inc. ("Aerie"), brings extensive ophthalmic industry expertise and insight to the Company's board. "Kiora has a compelling development pipeline, including KIO-301, a...
2021-12-15 7:00 AM EST
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
Salt Lake City, Utah--(Newsfile Corp. - December 14, 2021) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops. The study evaluated 24 healthy subjects and 21 patients diagnosed with ocular surface inflammation, a key driver of dry eye disease. The results demonstrated favorable safety and tolerability of KIO-101 as well as statistically significant improvements in conjunctival...
2021-12-14 7:15 AM EST